Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) — Cash Flow-to-Debt Ratio
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has a Cash Flow-to-Debt Ratio of -0.01x as of June 2026, meaning its operating cash flow of $-19.26 Million could theoretically repay 0% of its total liabilities ($3.66 Billion) in one year. See Amneal Pharmaceuticals, Inc. Class A Com financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Amneal Pharmaceuticals, Inc. Class A Common Stock Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Amneal Pharmaceuticals, Inc. Class A Common Stock across 11 annual periods. For the full cash flow conversion analysis, see AMRX cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for Amneal Pharmaceuticals, Inc. Class A Common Stock (2015–2025)
Year-by-year debt coverage analysis for Amneal Pharmaceuticals, Inc. Class A Common Stock. Check AMRX cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.09x | $339.99 Million | $3.67 Billion | ▲ +11.2% |
| 2024 | 0.08x | $295.10 Million | $3.55 Billion | ▼ -17.9% |
| 2023 | 0.10x | $345.58 Million | $3.41 Billion | ▲ +458.7% |
| 2022 | 0.02x | $65.10 Million | $3.59 Billion | ▼ -73.2% |
| 2021 | 0.07x | $241.82 Million | $3.57 Billion | ▼ -34.8% |
| 2020 | 0.10x | $379.00 Million | $3.65 Billion | ▲ +20117.5% |
| 2019 | 0.00x | $1.71 Million | $3.32 Billion | ▼ -99.3% |
| 2018 | 0.07x | $250.23 Million | $3.46 Billion | ▼ -46.9% |
| 2017 | 0.14x | $234.19 Million | $1.72 Billion | ▲ +65.3% |
| 2016 | 0.08x | $115.06 Million | $1.39 Billion | ▼ -5.5% |
| 2015 | 0.09x | $104.88 Million | $1.20 Billion | — |